Vaccinex Inc. (VCNX) is a Biotechnology: Pharmaceutical Preparations company listed on NASDAQ. There were no new wire items for VCNX in the last 30 days. The most recent was published Oct 7, 2026.
News · 26 weeks2-100%
2026-05-172026-11-08
Mix190d
- Other1(100%)
Activity · 52 weeks44 active days
Tap a day to see what happenedEarningsInsiderAnalystFilings and news
Latest news
25 items- PRSEMA4D Blockade Reshapes the Tumor Immune Environment in Neoadjuvant Melanoma StudyROCHESTER, N.Y., Oct. 07, 2026 (GLOBE NEWSWIRE) -- Vaccinex, Inc. a clinical-stage biotechnology company pioneering a differentiated approach to treating Cancer and Alzheimer’s disease (AD) through the inhibition of Semaphorin 4D (SEMA4D), today announced the publication in Nature Communications of results from an Emory University and Winship Cancer Institute-sponsored pilot study evaluating pepinemab in patients with metastatic melanoma. The publication represents an important milestone in an almost decade-long scientific partnership between Vaccinex and Winship investigators, focused on advancing the understanding of SEMA4D biology and its potential application in cancer immunotherapy. T
- PRVaccinex to Report New Biomarker Data and Plans for Phase 2B Clinical Trial of Pepinemab in AD at the Alzheimer’s Association International Conference in London on July 13, 2026ROCHESTER, N.Y., July 08, 2026 (GLOBE NEWSWIRE) -- Vaccinex, Inc., a clinical-stage biotechnology company pioneering a differentiated approach to treating Alzheimer’s disease (AD) through the inhibition of Semaphorin 4D (SEMA4D), today announced that it will present promising new biomarker data from its Phase 1b/2 trial to support plans for an enlarged randomized phase 2B SIGNAL-AD study of pepinemab for treatment for early Alzheimer’s disease at the Alzheimer’s Association International Conference in London, United Kingdom, on July 13, 2026. Elizabeth Evans, PhD, Chief Operating Officer and Senior VP Discovery and Translational Medicine, will chair the Featured Research Session and presen
- PRVaccinex Reports 2025 Annual Financial ResultsROCHESTER, N.Y., April 29, 2026 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (OTC:VCNX), a clinical-stage biotechnology company pioneering novel investigational antibody therapies in Alzheimer's, Huntington's disease, and cancer today released financial results for the year ended December 31, 2025. The financial statements have been posted on the company website. About Vaccinex, Inc. Vaccinex, Inc. is a clinical-stage immunotherapy company engaged in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs, including neurodegenerative diseases, cancer, and autoimmune disorders, and is currently initiating a new Phase 2b study in A
- PRVaccinex, Inc. Announces $60 million Agreement to Finance a Phase 2b clinical trial of pepinemab to treat Alzheimer's DiseaseROCHESTER, N.Y., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating Alzheimer's disease (AD) by inhibiting semaphorin 4D (SEMA4D) induced pathology in brain, today announced that it has entered into a $60 million revenue sharing agreement with Pepinemab Development Venture, LP (PDV) to continue advancing development of its pepinemab anti-SEMA4D antibody in an enlarged phase 2b clinical trial for treatment of AD. PDV LP is an investment entity established by FCMI, an existing Vaccinex investor. Albert Friedberg is Chairman of FCMI and of the Vaccinex Board. The agreements provide that, in exchange
- PRVaccinex to Report Promising New Clinical Results of Neoadjuvant Treatment with Pepinemab to Enhance Immunotherapy in Patients with Head and Neck Cancer at ASCO Annual MeetingROCHESTER, N.Y., May 27, 2025 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (NASDAQ:VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and Alzheimer's disease (AD) through the inhibition of Semaphorin 4D (SEMA4D), today announced that it will present new data characterizing the unique mechanism of pepinemab to enhance immune responses to checkpoint therapies in the neoadjuvant setting that are associated with improved pathologic response in patients with head and neck cancer. Lead investigator and collaborator, Conor Steuer, MD from Winship Cancer Center at Emory University, will present results at the 2025 Annual Meeting of Clinical Oncology (ASCO)
- PRVaccinex to Report Promising New Clinical Data Revealing Pepinemab's Unique Mechanism to Enhance Immunotherapy at Annual Meeting of American Association for Cancer Research (AACR)Neoadjuvant treatment with pepinemab appears to induce abundant, mature lymphoid structures that correlate with durable clinical benefit of immunotherapy in patients with metastatic melanoma. Pepinemab, Semaphorin 4D blocking immunotherapy, also appears to induce the formation of efficient lymphoid structures in "cold" tumors of patients with recurrent and metastatic head and neck cancer. ROCHESTER, N.Y., April 21, 2025 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (NASDAQ:VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and Alzheimer's disease (AD) through the inhibition of Semaphorin 4D (SEMA4D), today announced that it will present exciting ne
- SECSEC Form 10-K filed by Vaccinex Inc.10-K - VACCINEX, INC. (0001205922) (Filer)
- SECSEC Form NT 10-K filed by Vaccinex Inc.NT 10-K - VACCINEX, INC. (0001205922) (Filer)
- SECSEC Form 15-12G filed by Vaccinex Inc.15-12G - VACCINEX, INC. (0001205922) (Filer)
- SECSEC Form EFFECT filed by Vaccinex Inc.EFFECT - VACCINEX, INC. (0001205922) (Filer)
- SECSEC Form EFFECT filed by Vaccinex Inc.EFFECT - VACCINEX, INC. (0001205922) (Filer)
- SECSEC Form EFFECT filed by Vaccinex Inc.EFFECT - VACCINEX, INC. (0001205922) (Filer)
- SECSEC Form EFFECT filed by Vaccinex Inc.EFFECT - VACCINEX, INC. (0001205922) (Filer)
- SECSEC Form EFFECT filed by Vaccinex Inc.EFFECT - VACCINEX, INC. (0001205922) (Filer)
- SECSEC Form EFFECT filed by Vaccinex Inc.EFFECT - VACCINEX, INC. (0001205922) (Filer)
- SECSEC Form EFFECT filed by Vaccinex Inc.EFFECT - VACCINEX, INC. (0001205922) (Filer)
- SECSEC Form EFFECT filed by Vaccinex Inc.EFFECT - VACCINEX, INC. (0001205922) (Filer)
- SECSEC Form EFFECT filed by Vaccinex Inc.EFFECT - VACCINEX, INC. (0001205922) (Filer)
- SECSEC Form EFFECT filed by Vaccinex Inc.EFFECT - VACCINEX, INC. (0001205922) (Filer)
- SECSEC Form EFFECT filed by Vaccinex Inc.EFFECT - VACCINEX, INC. (0001205922) (Filer)
- SECSEC Form EFFECT filed by Vaccinex Inc.EFFECT - VACCINEX, INC. (0001205922) (Filer)
- SECSEC Form EFFECT filed by Vaccinex Inc.EFFECT - VACCINEX, INC. (0001205922) (Filer)
- SECSEC Form EFFECT filed by Vaccinex Inc.EFFECT - VACCINEX, INC. (0001205922) (Filer)
- SECSEC Form EFFECT filed by Vaccinex Inc.EFFECT - VACCINEX, INC. (0001205922) (Filer)
- SECSEC Form POS AM filed by Vaccinex Inc.POS AM - VACCINEX, INC. (0001205922) (Filer)
VCNX FAQ
7 questionsWhat does Vaccinex Inc. do?
Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs. The company offers its products for the treatment of cancer, neurodegenerative diseases, and autoimmune disorders. Its lead product candidate is pepinemab, a humanized monoclonal antibody that is in Phase 1 and 2 clinical trials for the treatment of non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), Huntington's disease, Alzheimer's disease, osteosarcoma, and melanoma. The...What is the latest news on VCNX?
Quantisnow has not tracked any new filings, ratings or press releases for VCNX in the last 30 days. The most recent wire item was published on October 7, 2026.Where does VCNX stock trade?
Vaccinex Inc. (VCNX) is listed on NASDAQ.What sector and industry is VCNX in?
Vaccinex Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Vaccinex Inc. go public?
Vaccinex Inc. (VCNX) completed its IPO in 2018.What companies are similar to VCNX?
Notable peers in the same industry include ABT (Abbott Laboratories), MRK (Merck & Company Inc.), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), NVS (Novartis AG). Compare VCNX side-by-side with any of them on Quantisnow.How can I track VCNX on Quantisnow?
Quantisnow aggregates Vaccinex Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow VCNX to receive live email and push alerts on every new disclosure.